Cleveland Biolabs, Inc. (CBLI) Cash Flow Statement

Click line-items for a historical chart and %

CASH FLOWS FROM OPERATING ACTIVITIES
Net income/(Loss)	-10.79M
Adjustments to reconcile net income/(loss) to net cash used in operating activities:
Depreciation	94.93K
Amortization
Noncash salaries and consulting expense	635.01K
Warrant issuance costs
Change in value of warrant liability
Changes in operating assets and liabilities:
Accounts receivable	-435.28K
Other current assets	-74.13K
Other long term assets
Deposits
Accounts payable	-286.38K
Deferred revenue	-219.28K
Accrued expenses
Accrued bonuses	643.88K
Net cash used in operating activities	-7M
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of short-term invesments
Purchase of equipment	-20.05K
Costs of patents pending
Net cash used in investing activities	1.3M
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock
Noncontrolling interest capital contribution to Incuron, LLC
Financing costs on common stock offering
Cash warrant issuance costs
Warrant exercise fees
Exercise of options
Exercise of warrants
Net cash provided by financing activities	-16.97K
Effect of exchange rate change on cash and equivalents	-157.92K
INCREASE IN CASH AND EQUIVALENTS	-5.88M
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD	25.65M
CASH AND EQUIVALENTS AT END OF PERIOD	19.77M

Entities mentioned with CBLI

View All Entities